Biocon Expands Settlement For Stelara Rival To Cover Global Markets
Indian Biosimilars Giant Had Previously Struck Ustekinumab Deal For US Entry
Biocon Biologics has announced a deal with Janssen that will clear the way for the Indian biosimilars giant to launch its Bmab 1200 ustekinumab rival to Stelara in Europe, the UK, Canada and Japan.
